Use of Octreotide in the Management of Severe Duodenal Bleeding after Unrelated-Donor Bone Marrow Transplantation

2003 ◽  
Vol 78 (2) ◽  
pp. 176-177 ◽  
Author(s):  
Kazuteru Ohashi ◽  
Yuji Tanaka ◽  
Hideki Akiyama ◽  
Hisashi Sakamakia ◽  
Masaki Sanaka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Unrelated Donor ◽  
Donor Bone Marrow ◽  
Duodenal Bleeding

Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse

2015 ◽  
Vol 94 (7) ◽  
pp. 1139-1148 ◽  
Author(s):  
Nobuhiko Imahashi ◽  
◽  
Haruhiko Ohashi ◽  
Seitaro Terakura ◽  
Kotaro Miyao ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Unrelated Donor ◽  
Donor Bone Marrow

scholarly journals Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia

Blood ◽  
2006 ◽  
Vol 109 (5) ◽  
pp. 2256-2262 ◽  
Author(s):  
John E. Wagner ◽  
Mary Eapen ◽  
Margaret L. MacMillan ◽  
Richard E. Harris ◽  
Ricardo Pasquini ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
T Cell ◽  
Fanconi Anemia ◽  
Marrow Transplantation ◽  
Survival Rates ◽  
Conditioning Regimen ◽  
Unrelated Donor ◽  
Donor Bone Marrow ◽  
The Impact

AbstractBone marrow transplantation (BMT) is the only known cure for the hematologic manifestations of Fanconi anemia (FA). Potential benefits of unrelated donor BMT for FA, however, have been severely limited by graft rejection and treatment-related mortality with resultant poor survival. Therefore, we evaluated the impact of potential prognostic factors on hematopoietic recovery, graft-versus-host disease (GVHD), and mortality in 98 recipients of unrelated donor BMT who received transplants between 1990 and 2003. Probabilities of neutrophil (89% vs 69%; P = .02) and platelet (74% vs 23%; P < .001) recovery were higher after fludarabine-containing regimens than nonfludarabine-containing regimens. Risks of acute GVHD (relative risk [RR], 4.29; P < .001) were higher with non–T-cell–depleted grafts. The day-100 mortality rate was significantly higher after nonfludarabine-containing regimens than fludarabine-containing regimens (65% vs 24%, respectively; P < .001). Corresponding 3-year adjusted overall survival rates were 13% versus 52% (P < .001). In addition, mortality was higher in recipients who were older (> 10 years), who were cytomegalovirus (CMV) seropositive, and who received more than 20 blood product transfusions before BMT. Based on these results, significant practice changes are suggested: use of a fludarabine-containing conditioning regimen in the context of T-cell–depleted marrow allografts, and earlier referral for transplantation prior to excessive transfusions in patients with marrow failure.

Sign in / Sign up

Export Citation Format

Share Document